BUZZ-Hansoh jumps most in 19 months on annual profit beat, Citi lifts target price

Citigroup Inc.

Citigroup Inc.

C

0.00

** Shares of China's Hansoh Pharmaceutical Group 3692.HK jump 8.6% to HK$35.94, on track for biggest one-day pct gain since August 2024

** Stock hits the highest point since February 24 in the third straight session of gains; top pct gainer in the Hang Seng Biotech Index .HSBIO, which slips 0.2%

** Hansoh, a Roche ROG.S partner, reports a 27% y/y rise in 2025 annual profit, beating market expectations and boosted by income from innovative medicines and business development deals

** Citi maintains "buy" rating on Hansoh and lifts target price to HK$49 from HK$45 as it raises FY26/27E revenue forecasts by 8%/9% to reflect latest sales trend and business development collaboration revenue

** YTD, stock down 1.4%, benchmark Hang Seng Index .HSI down 3.7%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.